NcXHF

BONE HEALTH AND ENDOCRINE THERAPY IN BREAST OR PROSTATE CANCER
FUTURE DIRECTIONS
With our aging population, it is expected that the number of
people affected by osteoporosis and with cancer will increase.
The need to co-manage these diagnoses will continue into the
foreseeable future. Areas of osteoporosis research include
targeting sclerostin and thereby potentially inducing osteoanabolic
activity, which may or may not be appropriate for
use in patients with a history of breast or prostate cancer. As
novel bone signaling pathways are targeted, the effect on cancer
signaling must also be considered. Likewise, as novel anticancer
therapies are developed, their effects on bone health
should be investigated.
There are insuffıcient data to guide all possible clinically
relevant bone and endocrine situations faced in the medical
oncology clinic. Indeed, there are many questions that have
not been formally studied, most notably where fractures are
the primary endpoint. A fundamental goal of bone health
care is to prevent fractures. BMD is a surrogate measurement
used in risk assessment for fracture but is not the endgame. It
can be challenging to study rates of fractures because of the
large number of patients and the long duration of follow-up
needed. Thankfully, it is very likely that in the future of “Big
Data” and the ASCO program CancerLinQ, knowledge of the
bone health of every patient will provide answers to fracturerelated
and other questions. There is reason to be optimistic
that CancerLinQ and future research will reveal patterns of
events and patterns of care that will inform future guidelines
to improve bone outcomes.
Disclosure of Potential Conflicts of Interest
Relationships are considered self-held and compensated unless otherwise noted. Relationships marked “L” indicate leadership positions. Relationships marked “I” are those held by an immediate
family member; those marked “B” are held by the author and an immediate family member. Institutional relationships are marked “Inst.” Relationships marked “U” are uncompensated.
Employment: None. Leadership Position: None. Stock or Other Ownership Interests: None. Honoraria: None. Consulting or Advisory Role: None.
Speakers’ Bureau: None. Research Funding: Catherine H. Van Poznak, Amgen (Inst), Novartis (Inst). Patents, Royalties, or Other Intellectual Property:
Catherine H. Van Poznak, UpToDate. Expert Testimony: None. Travel, Accommodations, Expenses: None. Other Relationships: None.
References
1. American Cancer Society. http://www.cancer.org/cancer/breastcancer/
detailedguide/breast-cancer-key-statistics. Accessed February 04, 2015.
2. American Cancer Society http://www.cancer.org/cancer/prostatecancer/
detailedguide/prostate-cancer-key-statistics. Accessed February 04, 2015.
3. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention
and treatment of osteoporosis. Osteoporos Int. 2014;25:2359-2381.
4. National Institute of Health, National Institute of Arthritis and Musculoskeletal
and Skin Diseases. http://www.niams.nih.gov/health_info/
bone/osteoporosis/overview.asp. Accessed February 04, 2015.
5. World Health Organization. http://www.iofbonehealth.org/sites/
default/fıles/WHO_Technical_Report-2007.pdf. Accessed February
04, 2015.
6. Siris ES, Adler R, Bilezikian J, et al. The clinical diagnosis of osteoporosis:
a position statement from the National Bone Health Alliance Working
Group. Osteoporos Int. 2014;25:1439-1443.
7. Raisz LG. Clinical practice. Screening for osteoporosis N Engl J Med.
2005;353:164-171.
8. National Institutes of Health. http://www.nlm.nih.gov/medlineplus/
osteoporosis.html. Accessed February 04, 2015.
9. Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/
fastats/osteoporosis.htm. Accessed February 04, 2015.
10. U.S. Department of Health and Human Services Agency for Healthcare
Research and Quality. http://effectivehealthcare.ahrq.gov/index.cfm/
search-for-guides-reviews-and-reports/?pageactiondisplayproduct&
productid1049&PCTOLAND. Accessed February 04, 2015.
11. National Osteoporosis Foundation. http://nof.org. Accessed February
04, 2015.
12. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and
conservation of the adult skeleton. Endocr Rev. 2002;23:279-302.
13. Offıce of the Surgeon General (US). Bone health and osteoporosis: a
report of the Surgeon General. Rockville, MD 2004. http://www.ncbi.
nlm.nih.gov/books/NBK45513. Accessed February 04, 2015.
14. Eastell R. Management of osteoporosis due to ovarian failure. . Med Pediatr
Oncol. 2003;41:222-227.
15. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone
mineral density in postmenopausal women with breast cancer. N Engl
J Med. 1992;326:852-856.
16. Eriksson S, Eriksson A, Stege R, et al. Bone mineral density in patients
with prostatic cancer treated with orchidectomy and with estrogens.
Calcif Tissue Int. 1995;57:97-99.
17. Lipton A, Smith MR, Ellis GK, et al. Treatment-induced bone loss and
fractures in cancer patients undergoing hormone ablation therapy: effıcacy
and safety of denosumab. Clin Med Insights Oncol. 2012;6: 287-
299.
18. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects
of chemotherapy and hormonal therapy for early breast cancer on
recurrence and 15-year survival: an overview of the randomised trials.
Lancet. 2005;365:1687-1717.
19. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical
Oncology clinical practice guideline: update on adjuvant endocrine
therapy for women with hormone receptor-positive breast cancer. J Clin
Oncol. 2010;28:3784-3796.
20. Love RR, Barden HS, Mazess RB, et al. Effect of tamoxifen on lumbar
spine bone mineral density in postmenopausal women after 5 years.
Arch Intern Med. 1994;154:2585-2588.
21. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant
tamoxifen to 10 years versus stopping at 5 years after diagnosis of
oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Lancet. 2013;381:805-816.
22. Vehmanen L, Elomaa I, Blomqvist C, et al. Tamoxifen treatment after
adjuvant chemotherapy has opposite effects on bone mineral density in
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e573